Study:
Clinical Study to Assess Entry of Chemotherapeutic Agents Into Brain Metastases in Women With Breast Cancer
Rationale:
Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal
antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. Studying samples of tumor tissue and blood from
patients may help doctors understand how well these drugs can be carried to the brain.
Purpose:
More definitive knowledge of the penetration of chemotherapeutic and other agents
into the brain is necessary for the future rational design of drug and drug regimens that
target brain metastases. This clinical trial is studying how well capecitabine,
cyclophosphamide, doxorubicin, gemcitabine, lapatinib, paclitaxel, trastuzumab, or
vinorelbine penetrates brain tumors.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Breast Cancer
Metastatic Cancer |
Drug: capecitabine
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: gemcitabine hydrochloride
Drug: lapatinib ditosylate
Drug: paclitaxel
Drug: vinorelbine ditartrate
Drug: Trastuzumab |
N/A |
Verified by
Case Comprehensive Cancer Center
January, 2013
Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00795678
Study Type: Interventional
Study Design: Observational Model: Case-Only, Time Perspective: Prospective
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
David M. Peereboom, MD., Principal Investigator
Robert Weil, MD., Principal Investigator